Weight Loss

On Thursday, Kailera Therapeutics Inc. (NASDAQ:KLRA) priced its initial public offering of 39.06 million shares at $16.00 per share, with gross proceeds of around $625 million. In addition, Kailera has granted the underwriters an option to purchase up to an additional 5.86 million shares. Biotech...

Early prescription data for Eli Lilly and Co.'s (NYSE:LLY) newly launched obesity pill suggest a measured start compared to Novo Nordisk A/S' (NYSE:NVO) oral Wegovy, as investors track early traction in a rapidly evolving weight-loss drug market dominated by injectables. Early Prescription Trends...

On Thursday, Eli Lilly and Co. (NYSE:LLY) reported positive topline results from its Phase 3 ACHIEVE-4 trial of its oral drug Foundayo (orforglipron) for weight loss. The study showed that orforglipron met the primary goal of cardiovascular safety compared with insulin glargine in adults with type...

GoodRx Holdings, Inc. (NASDAQ:GDRX) shares are up on Wednesday as the company expands access to Novo Nordisk A/S’ (NYSE:NVO) Wegovy HD, a higher dose GLP-1 treatment available for self-pay patients at $399 per month. • GoodRx Holdings shares are advancing steadily. What’s driving...

Eli Lilly and Co. (NYSE:LLY) on Wednesday announced that Foundayo (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems. Access Expands Across LillyDirect, Telehealth And Retail Pharmacies Last week, the U.S. Food and Drug Administration (FDA)...

Structure Therapeutics Inc(NASDAQ:GPCR) shares are up on Wednesday, probably in reaction to the U.S. Food and Drug Administration (FDA) approval of a similar drug for obesity. • What’s the outlook for GCPR shares? FDA Approves Eli Lilly's Oral Weight Loss On Wednesday, the FDA approved...

Eli Lilly (NYSE:LLY) shares rose on Wednesday after the FDA approved Foundayo, a new oral weight-loss drug, strengthening the company's position in the obesity market. In the ATTAIN-1 trial, adults on the highest dose lost an average of 27 pounds, or 12.4% of body weight. The once-daily pill will...

Novo Nordisk A/S (NYSE:NVO) on Tuesday introduced a multi-month subscription program for its obesity treatment Wegovy (semaglutide), aiming to make pricing more predictable for self-pay patients and improve long-term adherence. Earlier in March, the U.S. Food and Drug Administration (FDA) approved...

Wave Life Sciences Ltd. (NASDAQ:WVE) shares are tumbling on Thursday following the announcement of interim Phase 1 data from its INLIGHT trial. Six-Month Data Shows Visceral Fat Reduction And Lean Mass Stability At the six-month follow-up, a single 240 mg dose of WVE-007 demonstrated significant...

The United Laboratories International Holdings Limited and Novo Nordisk A/S (NYSE:NVO) reported Wednesday topline data from a phase 2 trial in China showing that UBT251, a triple receptor agonist. Semaglutide is a key ingredient in the famed Wegovy and Ozempic. UBT251 is designed to challenge Eli...

More than 80 global executives gathered in Beijing for the China Development Forum, signaling renewed corporate interest in the Chinese market despite ongoing geopolitical tensions. Leaders from major multinationals, including Apple Inc. (NASDAQ:AAPL) and Eli Lilly and Co. (NYSE:LLY), emphasized...

The landscape for weight-loss and diabetes treatment shifted dramatically over the weekend as at least six Indian pharmaceutical companies introduced generic versions of Novo Nordisk A/S’ (NYSE:NVO) blockbusters Ozempic and Wegovy. Following the expiration of the Indian patent for semaglutide...

The U.S. Food and Drug Administration (FDA) on Thursday approved a higher-dose version of Novo Nordisk A/S’ (NYSE:NVO) blockbuster weight-loss drug, Wegovy, marking an expansion of its treatment portfolio for adults with obesity. • Novo Nordisk shares are experiencing downward...

Eli Lilly and Co (NYSE:LLY) shares are down on Thursday. The company released news regarding its investigational drug, retatrutide, which has shown promising results in clinical trials. Eli Lilly Retatrutide Shows Strong A1C Reduction And Weight Loss Retatrutide is an investigational once-weekly...

Eli Lilly & Co. (NYSE:LLY) shares faced downward pressure on Tuesday after HSBC analysts turned bearish, suggesting that the weight-loss market is overly optimistic regarding revenue potential. Analyst Rajesh Kumar downgraded the U.S. drugmaker from Hold to Reduce, while cutting the price...